1. Home
  2. NUCL vs KZIA Comparison

NUCL vs KZIA Comparison

Compare NUCL & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Nuclear Energy Corp. Common stock

NUCL

Eagle Nuclear Energy Corp. Common stock

N/A

Current Price

$2.71

Market Cap

141.4M

ML Signal

N/A

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

N/A

Current Price

$5.36

Market Cap

125.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NUCL
KZIA
Founded
2023
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
141.4M
125.6M
IPO Year
2026
2002

Fundamental Metrics

Financial Performance
Metric
NUCL
KZIA
Price
$2.71
$5.36
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $27.22
AVG Volume (30 Days)
198.2K
★ 241.7K
Earning Date
10-13-2026
12-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$258.04
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.08
$4.86
52 Week High
$14.22
$17.40

Technical Indicators

Market Signals
Indicator
NUCL
KZIA
Relative Strength Index (RSI) 15.03 28.38
Support Level N/A $4.86
Resistance Level $6.58 $14.85
Average True Range (ATR) 0.39 0.68
MACD -0.08 -0.16
Stochastic Oscillator 0.50 9.86

Price Performance

Historical Comparison
NUCL
KZIA

About NUCL Eagle Nuclear Energy Corp. Common stock

Eagle Nuclear Energy Corp is a next-generation nuclear energy company that seeks to combine domestic uranium exploration and development with proprietary small modular reactor (SMR) technology. It holds rights to the mineable, measured, and indicated uranium deposit in the United States, known as the Aurora Uranium Project, located in southeastern Oregon. The Aurora Uranium Project includes the Aurora deposit, with an estimated resource of 32.75 million pounds (Indicated) and 4.98 million pounds (Inferred) of near-surface uranium, and the adjacent Cordex zone.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: